Hims & Hers Expands into Subscription-Based Blood Testing

The telehealth provider Hims & Hers is executing a significant strategic pivot, moving beyond its core business of distributing prescription medications to aggressively enter the preventive healthcare space. The company's new "Labs" initiative, a subscription service for comprehensive blood testing, positions it to capture a share of a multi-billion dollar market.

This strategic shift is backed by robust financial health. For the third quarter of 2025, Hims & Hers reported a 49% surge in revenue, reaching $599 million. The subscriber base grew to nearly 2.5 million, representing a 21% year-over-year increase. The company posted a net income of $16 million, with adjusted EBITDA exceeding $78 million.

However, the full-year outlook was tempered slightly. Management now anticipates full-year revenue in the range of $2.335 billion to $2.355 billion. Projected adjusted EBITDA is forecast between $307 million and $317 million. This cautious guidance reflects the broader competitive pressures and volatility within the telehealth sector.

The "Labs" Service: Details and Delivery

Unveiled by CEO Andrew Dudum on November 13, the new service offers two primary subscription tiers. The foundational package, priced at $199 per year, includes an annual blood test analyzing 50 biomarkers. For consumers seeking more granular data, a premium option costs $499 annually and provides two tests per year, covering over 120 biomarkers. Both tiers are complemented by physician-developed action plans and personalized treatment recommendations, provided they are deemed medically appropriate.

To support the national rollout, Hims & Hers has established a solid infrastructure through partnerships with Quest Diagnostics and other laboratory networks. This gives customers access to over 1,000 physical locations for blood draws across the country, ensuring scalability and maintaining consistent quality standards.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Evolving from Pharmacy to Holistic Health Partner

The launch of Labs signals a fundamental evolution for Hims & Hers. The company is strategically repositioning itself from a digital pharmacy focused on specific conditions to a comprehensive, data-driven health platform.

Dr. Pat Carroll, Chief Medical Officer, emphasized the importance of this move, stating, "Laboratory results are central to medical decision-making in primary care. Our goal is to make this process simpler, more personal, and more actionable for our members."

The company's roadmap indicates further expansion, with plans for at-home testing devices, additional biomarkers related to bone and brain health, and enhanced diagnostic capabilities for chronic conditions.

Potential Hurdles and Market Limitations

Despite the ambitious plans, the service faces certain constraints. Availability is not universal across all 50 U.S. states, and all test orders require approval from a licensed physician. These regulatory requirements pose potential hurdles that could slow the service's expansion and impact its overall market penetration.